NRX Pharmaceuticals, Inc. income statement NRXP

Annual Quarterly

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, NRX Pharmaceuticals, Inc. reported revenue of $1.1 million. It recorded a net loss of $16.5 million. The operating loss came to $6.5 million, an operating margin of -590.8%.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q2 FY2024 Jun 30, 2025	Q1 FY2024 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024	Q4 FY2023 Dec 31, 2023	Q3 FY2023 Sep 30, 2023
Revenue	—	1	1	0	0	0	0	—	—
Cost of revenue	—	1	1	—	—	—	—	—	—
Gross profit	—	0	0	—	—	—	—	—	—
Research and development	—	2	1	1 -74.5%	—	1 -59.1%	1 -81.6%	3 -43.1%	3 -19.7%
Selling, general and administrative	—	5	4	—	—	3 +38.8%	2 -3.3%	2 -65.5%	2 -50.2%
Operating income	—	-7	-5	-4 +54.4%	—	-2 +44.8%	-3 +48.0%	-4 +55.4%	-6 +36.5%
Income tax	—	0	0	0	0	0	0	—	—
Net income	—	-17	-1	-18 -101.7%	-6 +0.0%	-9 -109.6%	-2 +73.2%	-4 +57.7%	-6 +33.3%
Basic EPS	—	-0.44	-0.04	-0.98 +19.0%	—	-0.74 -38.1%	-0.15 +79.7%	-0.54 -248.7%	-0.74 -428.6%
Diluted EPS	—	—	—	—	—	—	—	—	-0.07 +50.0%
Weighted average shares, basic	—	38	32	18 +144.9%	—	12 +51.7%	11 +33.9%	8 -87.9%	8 -87.7%
Weighted average shares, diluted	—	—	—	—	—	—	—	—	82 +23.3%
Other measures
Depreciation and amortization	—	0	0	0 +9900.0%	0 +1900.0%	-1 -99100.0%	0 +1200.0%	0 +0.0%	0 +100.0%
EBITDA	—	-6	-5	-4 +55.7%	—	-3 +22.3%	-3 +48.4%	-4 +55.4%	-6 +36.5%
Interest coverage	—	-27.10x	-20.35x	—	—	—	—	—	—
Margins
Gross margin	—	38.69%	40.92%	—	—	—	—	—	—
Operating margin	—	-590.83%	-444.01%	—	—	—	—	—	—
Profit margin	—	-1,500.45%	-133.90%	—	—	—	—	—	—
EBITDA margin	—	-584.38%	-438.11%	—	—	—	—	—	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: NRXP (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Wilmington, DE
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1719406
Former names: Big Rock Partners Acquisition Corp. (until May 24, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.